News Daily News Slight Risk of Interstitial Lung Disease Seen With Certain DOACs Todd Neale November 23, 2022
News Daily News Apixaban Again Linked to Less Bleeding in AF Patients Michael O'Riordan October 31, 2022
News Daily News Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest Michael O'Riordan October 20, 2022
News Conference News TCT 2022 Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes Todd Neale September 18, 2022
News Daily News Early Rhythm Control Also May Help Lower-Risk AF Patients Todd Neale September 07, 2022
News Conference News ESC 2022 DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark L.A. McKeown August 30, 2022
News Conference News ESC 2022 INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF Michael O'Riordan August 28, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Daily News Stroke, Bleeding Risks Key for Assessing Potential LAAO Benefit Todd Neale August 17, 2022
News Daily News After COVID-19, Unvaccinated at Risk for Long-term CVD Complications Michael O'Riordan August 16, 2022
News Daily News Postoperative AF ‘Not Benign,’ Just As Likely to Cause Stroke Yael L. Maxwell July 29, 2022
News Daily News Peridevice Leaks After LAA Occlusion Signal Poorer 5-Year Outcomes Todd Neale July 28, 2022
News Daily News Postop AF Portends Higher Risk of HF Hospitalization in the Next Few Years Caitlin E. Cox June 30, 2022
News Conference News TVT 2022 More Support for Single Antiplatelet Therapy After TAVI Michael O'Riordan June 10, 2022
News Daily News LAA Occlusion With Watchman Provides Good Early Results in China Todd Neale June 07, 2022
News Daily News NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes L.A. McKeown May 03, 2022
News Conference News HRS 2022 Registry Shows Watchman FLX Beating First-Gen Device for Early LAAO Outcomes Todd Neale May 02, 2022
News Conference News ACC 2022 Managing AF Patients Undergoing PCI—Some Lingering Questions Michael O'Riordan April 12, 2022